A 38-year-old woman presented with acute onset of severe pain in the left calf and foot after inhaling heroin. On examination, she had distal left lower extremity weakness and absent ankle jerk. EMG at 8 weeks suggested an axonal left sciatic neuropathy. HIV test was negative. Creatine kinase, erythrocyte sedimentation rate, and C-reactive protein were normal. MRI revealed prominent edema and enlargement of the left sciatic nerve without contrast enhancement (figure). She received weekly infusions of IV methylprednisolone leading to improvement in her symptoms and MRI findings. Recognized neuromuscular complications of acute heroin usage include mononeuropathy, polyradiculoplexopathy, and rhabdomyolysis secondary to possible inflammatory or toxic mechanisms.
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Teaching NeuroImages: Sciatic neuropathy after heroin abuse A 38-year-old woman presented with acute onset of severe pain in the left calf and foot after inhaling heroin. On examination, she had distal left lower extremity weakness and absent ankle jerk. EMG at 8 weeks suggested an axonal left sciatic neuropathy. HIV test was negative. Creatine kinase, erythrocyte sedimentation rate, and C-reactive protein were normal. MRI revealed prominent edema and enlargement of the left sciatic nerve without contrast enhancement (figure). She received weekly infusions of IV methylprednisolone leading to improvement in her symptoms and MRI findings. Recognized neuromuscular complications of acute heroin usage include mononeuropathy, polyradiculoplexopathy, and rhabdomyolysis secondary to possible inflammatory or toxic mechanisms.
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